Timothy John Ritchie

USPTO Granted Patents = 18 (Patent Applications = 4)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 9 (Patent Applications = 13)

Average Co-Inventor Count = 3.9

ph-index = 4

Forward Citations = 83(Granted Patents)

Location History:

Stevenage, GB (2010 - 2014)
London, GB (2005 - 2015)
Horsham, GB (2011 - 2015)
Ranco, IT (2017)
St Albans, GB (2024)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

Years Active: 2005-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11925632 - Isoquinoline derivatives for use in treating GLUT1 deficiency syndrome (2024-03-12),

2. 9849117 - Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists (2017-12-26),

3. 9567343 - Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists (2017-02-14),

4. 9102653 - Substituted quinazolinones as vanilloid antagonists (2015-08-11),

5. 9012451 - Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists (2015-04-21),

6. 8809528 - Quinazolinone derivatives useful as vanilloid antagonists (2014-08-19),

7. 8765743 - Compounds (2014-07-01),

8. 8658635 - Benzpyrazol derivatives as inhibitors of PI3 kinases (2014-02-25),

9. 8536169 - Compounds (2013-09-17),

10. 8357716 - Pyrazole derivatives used as CCR4 receptor antagonists (2013-01-22),

11. 8236803 - Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists (2012-08-07),

12. 8211902 - Quinazolinone derivatives useful as vanilloid antagonists (2012-07-03),

13. 8163743 - 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases (2012-04-24),

14. 7960399 - Quinazolinone derivatives useful as vanilloid antagonists (2011-06-14),

15. 7732435 - Chromone derivatives useful as antagonists of VR1 receptors (2010-06-08),

Title: The Inventor Spotlight: Timothy John Ritchie

Introduction:

Timothy John Ritchie, a prolific inventor hailing from Stevenage, GB, has made significant contributions to the field of pharmaceuticals with a total of 17 patents to his name.

Latest Patents:

Among his recent patents is the groundbreaking innovation involving Aza-bicycloalkyl ethers and their application as alpha7-nachr agonists. These compounds serve as alpha 7 nicotinic acetylcholine receptor (nAChR) agonists, showcasing his expertise in medicinal chemistry and drug development.

Career Highlights:

Ritchie has lent his talents to esteemed companies such as Novartis AG and Glaxo Group Limited, shaping the landscape of pharmaceutical research and development. His keen insight and inventive spirit have propelled him to the forefront of innovation within the industry.

Collaborations:

Collaborating with notable peers like Terance William Hart and Nigel James Parr, Ritchie has fostered a culture of innovation and excellence. Together, they have pushed the boundaries of pharmaceutical science, leading to the creation of novel compounds with promising pharmaceutical applications.

Conclusion:

In conclusion, Timothy John Ritchie stands as a beacon of ingenuity in the realm of pharmaceutical inventions. His dedication to cutting-edge research and development has brought forth groundbreaking solutions that have the potential to revolutionize the field. As he continues to push the boundaries of innovation, the future holds endless possibilities for this visionary inventor.

Is there anything else you would like to know about inventors, inventions, or patents?

This text is generated by artificial intelligence and may not be accurate.